Investigators will discover a set of new specific genes that determine the multiplicity of myeloma, the second most common cancer cancer.
Latina Agencia Medicin y Salud Pública
The demonstration demonstrates that the expression of the gene allows the classification of a better form in the patients in terms of survival.
The scientists from the Clinic and the Cima University of Navarre are conducting an international investigation that reveals a conjunction of new multiple myeloma genes. This discovery has allowed 40,511 new genes not codified until now, it has been named as a bad genome, they are implicated in the evolution of this cancer-specific cancer.
According to experts, the study demonstrated that the expression of these genes, together with the genetic interactions related to a malignancy in patients who have multiple myeloma, allow them to better classify survival results.
The results are published in the journal Leukemia, and open the door to the development of new therapeutic strategies based on ARN for this type of tumor.
This cancer is a disease that does not have a cure that originates in the medium usa. If a patient is treated very well, then his treatment and the second most frequent hematologic cancer.
Recent investigations into oncology have focused on studies of one molecule involved in the regulation of the genome and the expression of genes. This investigation has described an ARN molecule that allows new genes to be identified with a keychain in the origin and functioning of cancerous cells.
The initial study of the detection and definition of complete transcripts of the IncRNAs was performed in samples of 38 patients with multiple myeloma demonstrating their functionality. También hemos demonstrated its potential as biomarkers analyzing the multiple myeloma patient series in the latest, named CoMPass study ”, assured Xabier Agirre, researcher at Hemato- Oncology del Cima.
Therapeutic Dianas
On the clinical side, the co-director of the Hemato-Oncology Program, Felipe Prósper affirmed that in the clinical part, the expression of the IncRNAs can be demonstrated, together with the genetic interactions of the most prognostic patient with much more disease. to patients in need of their survival.